Neximmune Financial Statements From 2010 to 2024
| NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Check Neximmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neximmune's main balance sheet or income statement drivers, such as , as well as many indicators such as . Neximmune financial statements analysis is a perfect complement when working with Neximmune Valuation or Volatility modules.
Neximmune |
Neximmune Company Return On Equity Analysis
Neximmune's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neximmune Return On Equity | -1.96 |
Most of Neximmune's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Neximmune has a Return On Equity of -1.9648. This is 91.8% lower than that of the Biotechnology sector and 94.61% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Neximmune Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neximmune's current stock value. Our valuation model uses many indicators to compare Neximmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neximmune competition to find correlations between indicators driving Neximmune's intrinsic value. More Info.Neximmune is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neximmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neximmune's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Neximmune Financial Statements
Investors use fundamental indicators, such as Neximmune's revenue or net income, to determine how well the company is positioned to perform in the future. Although Neximmune's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |